First approved in 1989, clozapine is the only medication indicated for treatment-resistant schizophrenia. It's also indicated ...

If the FDA follows an advisory committee’s vote, it can potentially be a transformative step in the delivery of mental health ...

A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...

Morgan Stanley has upgraded Cytokinetics (CYTK) to overweight from equal weight while lowering its price target. Read more ...

It is available only through a restricted REMS program. The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults ...

Cytokinetics , Inc. (NASDAQ:CYTK), with a market capitalization of $5.65 billion, is approaching a pivotal moment in its journey to become a leading player in the cardiovascular therapeutics market.

The Feminist Majority Foundation, they were heroic. They collected over 700,000 petitions from people across the United ...

However, Spravato remains restricted under the FDA's REMS program due to its abuse potential. Investors will watch how this regulatory win impacts Johnson & Johnson's pharma segment ahead of earnings.

Given its potential for abuse and misuse, Spravato will be only available through the FDA's Risk Evaluation and Mitigation Strategy (REMS) Program.

Moreover, the FDA's increased scrutiny of cardiac myosin ... even with a potentially less burdensome REMS program. Aficamten's potentially less restrictive REMS program could be a significant ...

Morgan Stanley analyst Jeffrey Hung upgraded Cytokinetics (CYTK) to Overweight from Equal Weight with a price target of $67, down from $70. The ...

The drug's safety profile as a monotherapy is ... called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program. MDD affects an estimated 21 million adults in the U.S., and about ...